TARA
Protara Therapeutics, Inc. (TARA) 10Y Growth Potential Analysis (2026)
Overall Score
Growth
No revenue base is reported in the fresh TTM metrics, so there is no evidence of scalable top-line growth.
Profitability remains absent with zero gross, operating, EBITDA, and net margins in TTM data.
Profitability
TTM returns are deeply negative, including ROA of -39.8%, ROE of -41.7%, and ROIC of -46.8%.
Operating margins remain at 0% across the reported TTM ratios, indicating no earnings power yet.
Financial Health
Liquidity is strong with a current ratio of 11.0 and cash ratio of 1.28, supported by working capital of $132.8M.
Leverage is very low with debt-to-equity of 0.017 and debt-to-assets of 0.016, though solvency ratio remains negative due to ongoing losses.
Shareholder Returns
Free cash flow remains negative at -$65.2M TTM, limiting any near-term shareholder return capacity.
No dividend is paid and earnings remain negative, so capital returns are not currently supported by fundamentals.
Valuation
Traditional earnings and cash-flow multiples are not meaningful because TTM earnings and free cash flow are negative.
Book-based valuation is the main anchor, with price-to-book at 1.44 and tangible book value per share of $2.64.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Protara Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

